Patents Examined by David S. Romeo
-
Patent number: 7737257Abstract: The present invention relates to a novel connective tissue growth factor-3 protein which is a member of the growth factor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human connective tissue growth factor-3 protein. Connective tissue growth factor-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods for detecting and treating connective tissue related disorders.Type: GrantFiled: December 21, 2007Date of Patent: June 15, 2010Assignee: Human Genome Sciences, Inc.Inventors: Reinhard Ebner, Arvind Chopra, Steven M. Ruben
-
Patent number: 7732567Abstract: Methods and compositions for use in modulating the activity(s) of WISP-1 polypeptide are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize induction or secretion of HAS2, HA, CD44 or RHAMM by native human WISP-1 polypeptide in at least one type of mammalian cell. The invention also provides methods for in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian cells or pathological conditions associated with native WISP-1 polypeptides.Type: GrantFiled: October 20, 2008Date of Patent: June 8, 2010Assignee: Genentech, Inc.Inventors: Luc Desnoyers, Ellen Filvaroff
-
Patent number: 7723473Abstract: This invention is drawn to methods of using peptide-based antagonists of TGF-beta to facilitate the healing of cutaneous wounds that includes burns, lacerations and scrapes. The administration of peptide TGF-beta antagonists to wounds results in reduced scarring, wound contraction and deposition of extracellular matrix components, and increased rates of re-epithelialization during wound healing.Type: GrantFiled: May 11, 2006Date of Patent: May 25, 2010Assignee: St. Louis UniversityInventor: Jung San Huang
-
Patent number: 7723486Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).Type: GrantFiled: February 8, 2006Date of Patent: May 25, 2010Assignees: Optein, Inc., Genzyme CorporationInventors: Steven R. Ledbetter, Celia P. Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
-
Patent number: 7718173Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 10, 2002Date of Patent: May 18, 2010Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
-
Patent number: 7713933Abstract: The present invention concerns stimulators of Activin and/or Inhibin for use in promoting the healing of wounds and fibrotic disorders with reduced scarring, together with medicaments and methods for promoting the healing of wounds and fibrotic disorders with reduced scarring.Type: GrantFiled: September 5, 2003Date of Patent: May 11, 2010Assignee: Renovo LimitedInventor: Mark W. J. Ferguson
-
Patent number: 7700107Abstract: The present invention relates to synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid ? which can be used alone or conjugated to an immunostimulatory molecule in an immunizing composition for inducing an immune response to amyloid ? peptides and amyloid deposits.Type: GrantFiled: September 19, 2008Date of Patent: April 20, 2010Assignee: New York UniversityInventors: Blas Frangione, Thomas Wisniewski, Einar M. Sigurdsson
-
Patent number: 7700101Abstract: The present invention provides reagents, compounds, compositions, and methods relating to novel interactions of the extracellular domain of LRP5, HBM (a variant of LRP5), and/or LRP6 with Dkk, including Dkk-1. The various nucleic acids, polypeptides, antibodies, assay methods, diagnostic methods, and methods of treatment of the present invention are related to and impact on Dkk, LRP5, LRP6, HBM, and Wnt signaling. Dkk, LRP5, LRP6, HBM, and Wnt are implicated in bone and lipid cellular signaling. Thus, the present invention provides reagents and methods for modulating lipid levels and/or bone mass and is useful in the treatment and diagnosis of abnormal lipid levels and bone mass disorders, such as osteoporosis.Type: GrantFiled: January 22, 2007Date of Patent: April 20, 2010Assignees: Wyeth, Oscient Pharmaceuticals CorporationInventors: Kristina M. Allen, Anthony Anisowicz, Veronique Damagnez, John A. Robinson, Paul J. Yaworsky, Bheem M. Bhat
-
Patent number: 7674769Abstract: Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog, preferably at low doses to avoid adverse side effects.Type: GrantFiled: October 15, 2002Date of Patent: March 9, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventor: Abla Creasey
-
Patent number: 7674620Abstract: The present disclosure is directed to improved methods for efficiently producing neuroprogenitor cells and differentiated neural cells such as dopaminergic neurons and serotonergic neurons from pluripotent stem cells, for example human embryonic stem cells. Using the disclosed methods, cell populations containing a high proportion of cells positive for tyrosine hydroxylase, a specific marker for dopaminergic neurons, have been isolated. The neuroprogenitor cells and terminally differentiated cells of the present disclosure can be generated in large quantities, and therefore may serve as an excellent source for cell replacement therapy in neurological disorders such as Parkinson's disease.Type: GrantFiled: March 11, 2004Date of Patent: March 9, 2010Assignee: Reliance Life Sciences Pvt. Ltd.Inventors: Satish Mahadeorao Totey, Geeta Ravindran
-
Patent number: 7671018Abstract: New uses of proteoglycans to bind and present growth factors, methods of accelerating wound, tissue or bone repair using such proteoglycans, pharmaceutical compositions of such proteoglycans, and scaffolds coated with such proteoglycans are disclosed. The proteoglycan of the invention is derived from domain I or perlecan.Type: GrantFiled: August 27, 2001Date of Patent: March 2, 2010Assignee: University of DelawareInventors: Daniel D. Carson, Mary C. Farach-Carson, Margaret French, Ronald Gomes, Rupert Timpl
-
Patent number: 7667005Abstract: The present invention relates to a polypeptide having an activity of suppressing aging; DNA encoding the polypeptide; a method for improving livestock, using the DNA; a recombinant DNA prepared by inserting the DNA into a vector; a transformant harboring the recombinant; a method for preparing the polypeptide of the present invention, using the transformant; an antibody which recognizes the polypeptide; a ligand for the polypeptide of the present invention; a compound inhibiting specific binding between the polypeptide and ligand of the present invention; a compound enhancing the expression of an aging-suppressing gene encoding the aging-suppressing polypeptide of the present invention; an oligonucleotide comprising a sequence of 10 to 50 nucleotides in the nucleotide sequence of the DNA; and a therapeutic agent for a syndrome resembling premature aging, a therapeutic agent for adult diseases or an aging-suppressing agent, using the same.Type: GrantFiled: March 12, 2008Date of Patent: February 23, 2010Assignee: Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc.Inventors: Youichi Nabeshima, Makoto Kuroo, Susumu Sekine, Akihiro Iida
-
Patent number: 7645451Abstract: Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and n which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: February 28, 2005Date of Patent: January 12, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventor: Sean A. McCarthy
-
Patent number: 7642237Abstract: The invention concerns a protein of the TGF-? family, the DNA coding therefor and a pharmaceutical composition containing the protein.Type: GrantFiled: March 16, 2004Date of Patent: January 5, 2010Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hoetten, Helge Neidhardt, Michael Paulista
-
Patent number: 7638495Abstract: The present invention relates to compositions comprising excipients or solubilizing agents for proteins. The invention relates to the discovery that a peptide derived from the N-terminus extension of the T266 isoform of rhBMP-2 has properties that enhance the solubility of proteins. The invention also relates to methods of resolubilizing a protein that has precipitated, by contacting the protein with a peptide comprised of the 17 amino acid extension of the T266 isoform of rhBMP-2. The invention also relates to methods of increasing the solubility of a protein by contacting the protein with a peptide comprised of the 17 amino acid extension of the T266 isoform of rhBMP-2.Type: GrantFiled: June 4, 2007Date of Patent: December 29, 2009Assignee: WyethInventors: Pilarin Elizabeth Louise Nichols, Bernardo Perez-Ramirez
-
Patent number: 7632808Abstract: The present invention concerns the use of biologically active MP52 or/and MP121 for the treatment and prevention of diseases of the nervous system or/and for the treatment of neuropathological situations which are caused by ageing of the nervous system. A pharmaceutical agent according to the invention for the treatment and prevention of diseases of the nervous system or/and for treating neuropathological situations which are caused by ageing of the nervous system therefore contains biologically active MP52 or/and MP121 as the active substance.Type: GrantFiled: February 3, 2003Date of Patent: December 15, 2009Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von PharmakaInventors: Gertrud Hötten, Jens Pohl, Rolf Bechtold, Michael Paulista, Klaus Unsicker
-
Patent number: 7629146Abstract: The invention relates to fragments of an amino acid sequence of mature, full length 24 kDa fibroblast growth factor-2 or an analog thereof. The fragments have an activity that inhibits the migration of cultured cells as well as inhibiting angiogenesis, tumor growth, or any other processes that involve the migration of cells in vivo. This fragment does not stimulate the proliferation of cells which is in contrast to activity shown by the mature, full-length 24 kDa fibroblast growth factor-2. The present invention also relates to a DNA molecule encoding the fragment, an expression vector and a transformed host containing the DNA molecule, and a method of producing the protein by culturing the transformed host. Moreover, the present invention relates to a therapeutic composition the 24 kDa fibroblast growth factor fragment and a pharmaceutically acceptable carrier.Type: GrantFiled: October 6, 2006Date of Patent: December 8, 2009Assignee: The Scripps Research InstituteInventor: Eugene G. Levin
-
Patent number: 7629446Abstract: The present invention is directed to a novel product and method for isolating ectoparasite saliva proteins, and a novel product and method for detecting and/or treating allergic dermatitis in an animal. The present invention includes a saliva protein collection apparatus capable of collecting ectoparasite saliva proteins substantially free of contaminating material. The present invention also relates to ectoparasite saliva proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to obtain such proteins and to use such proteins to identify animals susceptible to or having allergic dermatitis. The present invention also includes therapeutic compositions comprising such proteins and their use to treat animals susceptible to or having allergic dermatitis.Type: GrantFiled: December 14, 2006Date of Patent: December 8, 2009Assignee: Heska CorporationInventors: Shirley W. Hunter, Lynda Wallenfels, Glenn R. Frank
-
Patent number: 7619062Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those peptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: March 14, 2005Date of Patent: November 17, 2009Assignee: Genentech, Inc.Inventors: Luc Desnoyers, Napoleone Ferrara, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Kenneth J. Hillan, William I. Wood, Ellen Filvaroff
-
Patent number: 7597886Abstract: Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and/or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.Type: GrantFiled: July 6, 2001Date of Patent: October 6, 2009Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Jian Ni, Craig A. Rosen, Jun Zhang